Journal of racial and ethnic health disparities · 2025
Optimising Pre-Eclampsia Screening in Black Women; a Secondary Analysis of Data from Non-Intervention Screening Studies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arechvo Anastasija, Syngelaki Argyro, Döbert Moritz, Varouxaki Anna Nektaria, Tan Min Yi, Poon Liona, von Dadelszen Peter, Nicolaides Kypros H, Magee Laura A
Аннотация
OBJECTIVE: To compare pre-eclampsia screening strategies among Black vs. White ethnicity women.
METHODS: Using data from prospective non-intervention cohort studies in Europe, we evaluated pre-eclampsia risk in singleton pregnancies. Risk was determined by clinical risk factor screening ('clinical'), 'clinical' with Black ethnicity as a moderate-risk factor ('clinical-modified'), and the Fetal Medicine Foundation competing-risks model at 11-13 weeks' gestation ('model11-13 ' for preterm pre-eclampsia) and 35-36 weeks ('model35-36 ' for late preterm/term pre-eclampsia). To compare screening performance, models' screen-positive rates were adjusted to match 'clinical' screening.
RESULTS: At 11-13 weeks, 61,174 pregnancies were screened; preterm pre-eclampsia occurred in 493 (0.8%). At an overall 11.2% screen-positive-rate, 'model11-13 ' (vs. 'clinical') detection of preterm pre-eclampsia almost doubled for Black (88.0% from 46.4%) and White (66.4% from 36.7%) women. For 'clinical-modified', the overall screen-positive-rate was 18.5% and the detection rate for 'model11-13 ' (vs. 'clinical-modified') was 94.0% from 85.0% for Black women, and 77.3% from 36.7% for White. At 35-36 weeks, 29,035 pregnancies were screened; subsequent pre-eclampsia occurred in 654 (2.3%). At an overall 10.9% screen-positive-rate, 'model35-36 ' (vs. 'clinical') detection of pre-eclampsia more than doubled for both Black (74.8% from 26.2%) and White (69.6% from 33.1%) women. For 'clinical-modified', the overall screen-positive-rate was 15.5% and the detection rate for 'model35-36 ' (vs. 'clinical-modified') was 84.1% from 85.0% for Black women, and 78.5% from 33.1% for White.
CONCLUSIONS: The screening performance of the competing-risks model is superior to that of clinical risk factor screening without and with addition of Black ethnicity as a moderate clinical risk factor.
METHODS: Using data from prospective non-intervention cohort studies in Europe, we evaluated pre-eclampsia risk in singleton pregnancies. Risk was determined by clinical risk factor screening ('clinical'), 'clinical' with Black ethnicity as a moderate-risk factor ('clinical-modified'), and the Fetal Medicine Foundation competing-risks model at 11-13 weeks' gestation ('model11-13 ' for preterm pre-eclampsia) and 35-36 weeks ('model35-36 ' for late preterm/term pre-eclampsia). To compare screening performance, models' screen-positive rates were adjusted to match 'clinical' screening.
RESULTS: At 11-13 weeks, 61,174 pregnancies were screened; preterm pre-eclampsia occurred in 493 (0.8%). At an overall 11.2% screen-positive-rate, 'model11-13 ' (vs. 'clinical') detection of preterm pre-eclampsia almost doubled for Black (88.0% from 46.4%) and White (66.4% from 36.7%) women. For 'clinical-modified', the overall screen-positive-rate was 18.5% and the detection rate for 'model11-13 ' (vs. 'clinical-modified') was 94.0% from 85.0% for Black women, and 77.3% from 36.7% for White. At 35-36 weeks, 29,035 pregnancies were screened; subsequent pre-eclampsia occurred in 654 (2.3%). At an overall 10.9% screen-positive-rate, 'model35-36 ' (vs. 'clinical') detection of pre-eclampsia more than doubled for both Black (74.8% from 26.2%) and White (69.6% from 33.1%) women. For 'clinical-modified', the overall screen-positive-rate was 15.5% and the detection rate for 'model35-36 ' (vs. 'clinical-modified') was 84.1% from 85.0% for Black women, and 78.5% from 33.1% for White.
CONCLUSIONS: The screening performance of the competing-risks model is superior to that of clinical risk factor screening without and with addition of Black ethnicity as a moderate clinical risk factor.